nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOA—Biogenic Amine Synthesis—HDC—hematologic cancer	0.00619	0.0613	CbGpPWpGaD
Linezolid—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC22A1—hematologic cancer	0.00513	0.0508	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—PER3—hematologic cancer	0.00482	0.0478	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—UCHL1—hematologic cancer	0.00429	0.0425	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—CRY1—hematologic cancer	0.0041	0.0406	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—PER2—hematologic cancer	0.0041	0.0406	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—CRY2—hematologic cancer	0.0041	0.0406	CbGpPWpGaD
Linezolid—MAOB—Dopamine metabolism—NQO1—hematologic cancer	0.00391	0.0387	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—SNCA—hematologic cancer	0.00375	0.0372	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—PER1—hematologic cancer	0.00311	0.0308	CbGpPWpGaD
Linezolid—Rivaroxaban—ABCB1—hematologic cancer	0.00297	1	CrCbGaD
Linezolid—MAOB—Alpha-synuclein signaling—FGR—hematologic cancer	0.0029	0.0287	CbGpPWpGaD
Linezolid—MAOA—Norepinephrine Neurotransmitter Release Cycle—SLC22A1—hematologic cancer	0.00268	0.0266	CbGpPWpGaD
Linezolid—MAOA—Dopamine metabolism—NQO1—hematologic cancer	0.00245	0.0243	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—LCK—hematologic cancer	0.00222	0.022	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—ARNTL—hematologic cancer	0.00221	0.0219	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—SYK—hematologic cancer	0.00183	0.0182	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.00166	0.0164	CbGpPWpGaD
Linezolid—MAOA—Neurotransmitter Release Cycle—SLC22A1—hematologic cancer	0.00136	0.0135	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—NQO1—hematologic cancer	0.00126	0.0124	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—SLC35B2—hematologic cancer	0.00119	0.0118	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.00115	0.0114	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—BAD—hematologic cancer	0.00115	0.0113	CbGpPWpGaD
Linezolid—MAOA—Serotonin Transporter Activity—IL1B—hematologic cancer	0.00113	0.0112	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—SOD2—hematologic cancer	0.000966	0.00957	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—FOXO1—hematologic cancer	0.000964	0.00955	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.000907	0.00899	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.000837	0.0083	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—MAPK14—hematologic cancer	0.000771	0.00764	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTO1—hematologic cancer	0.000768	0.00761	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—SLC35B2—hematologic cancer	0.000748	0.00741	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—RET—hematologic cancer	0.00074	0.00733	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—UGT1A1—hematologic cancer	0.000722	0.00715	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—FOS—hematologic cancer	0.000681	0.00675	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—SRC—hematologic cancer	0.000681	0.00675	CbGpPWpGaD
Linezolid—MAOB—Tryptophan metabolism—MDM2—hematologic cancer	0.000637	0.00631	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—MTR—hematologic cancer	0.000626	0.0062	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTT1—hematologic cancer	0.000596	0.0059	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.000521	0.00516	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.000505	0.005	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.0005	0.00495	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTO1—hematologic cancer	0.000482	0.00477	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000481	0.00476	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—UGT1A1—hematologic cancer	0.000453	0.00449	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTP1—hematologic cancer	0.000413	0.00409	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.000411	0.00408	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—MTR—hematologic cancer	0.000393	0.00389	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC22A1—hematologic cancer	0.000391	0.00387	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTM1—hematologic cancer	0.000379	0.00376	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTT1—hematologic cancer	0.000374	0.0037	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000371	0.00368	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—ADCY7—hematologic cancer	0.000358	0.00355	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CAMK2D—hematologic cancer	0.000319	0.00316	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GMPS—hematologic cancer	0.000316	0.00313	CbGpPWpGaD
Linezolid—MAOB—Metabolism—FTCD—hematologic cancer	0.000316	0.00313	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PHYH—hematologic cancer	0.000316	0.00313	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC22A1—hematologic cancer	0.000299	0.00297	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000294	0.00292	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SMPD3—hematologic cancer	0.000289	0.00287	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—ADCY7—hematologic cancer	0.000274	0.00272	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTP1—hematologic cancer	0.000259	0.00257	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000259	0.00256	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000257	0.00255	CbGpPWpGaD
Linezolid—MAOB—Metabolism—B3GAT1—hematologic cancer	0.000253	0.00251	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ASNS—hematologic cancer	0.000253	0.00251	CbGpPWpGaD
Linezolid—MAOB—Metabolism—DCK—hematologic cancer	0.000253	0.00251	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CAMK2D—hematologic cancer	0.000244	0.00242	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HDC—hematologic cancer	0.00024	0.00238	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000238	0.00236	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTM1—hematologic cancer	0.000238	0.00236	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CDA—hematologic cancer	0.000219	0.00217	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PC—hematologic cancer	0.000211	0.00209	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GBA—hematologic cancer	0.000204	0.00202	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC35B2—hematologic cancer	0.000204	0.00202	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000201	0.00199	CbGpPWpGaD
Linezolid—MAOA—Metabolism—FTCD—hematologic cancer	0.000199	0.00197	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PHYH—hematologic cancer	0.000199	0.00197	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GMPS—hematologic cancer	0.000199	0.00197	CbGpPWpGaD
Linezolid—MAOB—Metabolism—MTAP—hematologic cancer	0.000186	0.00185	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CREB1—hematologic cancer	0.000182	0.0018	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SMPD3—hematologic cancer	0.000182	0.0018	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL6R—hematologic cancer	0.000177	0.00176	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	0.000177	0.00176	CbGpPWpGaD
Linezolid—MAOB—Metabolism—FHL2—hematologic cancer	0.000166	0.00165	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AGRN—hematologic cancer	0.000163	0.00161	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ASNS—hematologic cancer	0.000159	0.00157	CbGpPWpGaD
Linezolid—MAOA—Metabolism—B3GAT1—hematologic cancer	0.000159	0.00157	CbGpPWpGaD
Linezolid—MAOA—Metabolism—DCK—hematologic cancer	0.000159	0.00157	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HMMR—hematologic cancer	0.000154	0.00153	CbGpPWpGaD
Linezolid—MAOB—Metabolism—IDH2—hematologic cancer	0.000154	0.00153	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—PRKCG—hematologic cancer	0.000154	0.00153	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HDC—hematologic cancer	0.00015	0.00149	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000149	0.00148	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000147	0.00146	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ARNTL—hematologic cancer	0.000145	0.00144	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CA9—hematologic cancer	0.000141	0.0014	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ACP5—hematologic cancer	0.000141	0.0014	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NCOR2—hematologic cancer	0.000139	0.00138	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CDA—hematologic cancer	0.000138	0.00136	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL1B—hematologic cancer	0.000135	0.00134	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CASP3—hematologic cancer	0.000135	0.00133	CbGpPWpGaD
Linezolid—MAOB—Metabolism—IDH1—hematologic cancer	0.000133	0.00132	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PC—hematologic cancer	0.000132	0.00131	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TXN—hematologic cancer	0.000131	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ABCC3—hematologic cancer	0.000131	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTO1—hematologic cancer	0.000131	0.0013	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—JUN—hematologic cancer	0.000131	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SPHK1—hematologic cancer	0.000129	0.00127	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GBA—hematologic cancer	0.000128	0.00127	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC35B2—hematologic cancer	0.000128	0.00127	CbGpPWpGaD
Linezolid—MAOB—Metabolism—UGT1A1—hematologic cancer	0.000124	0.00122	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.000123	0.00122	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—EP300—hematologic cancer	0.000121	0.0012	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CRABP1—hematologic cancer	0.00012	0.00119	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC22A1—hematologic cancer	0.00012	0.00119	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALOX5—hematologic cancer	0.000117	0.00116	CbGpPWpGaD
Linezolid—MAOA—Metabolism—MTAP—hematologic cancer	0.000117	0.00116	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	0.000114	0.00113	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CREB1—hematologic cancer	0.000114	0.00113	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NUP98—hematologic cancer	0.000113	0.00112	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—BRAF—hematologic cancer	0.000113	0.00112	CbGpPWpGaD
Linezolid—Vomiting—Vincristine—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Anorexia—Betamethasone—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Anorexia—Dexamethasone—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Urticaria—Prednisolone—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Asthenia—Cisplatin—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Pharyngitis—Epirubicin—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Fatigue—Triamcinolone—hematologic cancer	0.000111	0.000124	CcSEcCtD
Linezolid—Rash—Vincristine—hematologic cancer	0.00011	0.000123	CcSEcCtD
Linezolid—Dermatitis—Vincristine—hematologic cancer	0.00011	0.000123	CcSEcCtD
Linezolid—MAOB—Metabolism—ADCY7—hematologic cancer	0.00011	0.00109	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NCOA3—hematologic cancer	0.00011	0.00109	CbGpPWpGaD
Linezolid—Pain—Triamcinolone—hematologic cancer	0.00011	0.000123	CcSEcCtD
Linezolid—Headache—Vincristine—hematologic cancer	0.00011	0.000122	CcSEcCtD
Linezolid—MAOB—Metabolism—NUP214—hematologic cancer	0.000109	0.00108	CbGpPWpGaD
Linezolid—Nausea—Carmustine—hematologic cancer	0.000109	0.000122	CcSEcCtD
Linezolid—Vomiting—Mitoxantrone—hematologic cancer	0.000108	0.000121	CcSEcCtD
Linezolid—Vomiting—Irinotecan—hematologic cancer	0.000108	0.000121	CcSEcCtD
Linezolid—Nausea—Alitretinoin—hematologic cancer	0.000108	0.000121	CcSEcCtD
Linezolid—Convulsion—Prednisone—hematologic cancer	0.000108	0.000121	CcSEcCtD
Linezolid—Hypertension—Prednisone—hematologic cancer	0.000108	0.00012	CcSEcCtD
Linezolid—Rash—Irinotecan—hematologic cancer	0.000108	0.00012	CcSEcCtD
Linezolid—Rash—Mitoxantrone—hematologic cancer	0.000108	0.00012	CcSEcCtD
Linezolid—Dermatitis—Irinotecan—hematologic cancer	0.000107	0.00012	CcSEcCtD
Linezolid—Dermatitis—Mitoxantrone—hematologic cancer	0.000107	0.00012	CcSEcCtD
Linezolid—Chills—Methotrexate—hematologic cancer	0.000107	0.00012	CcSEcCtD
Linezolid—MAOB—Metabolism—ABCG2—hematologic cancer	0.000107	0.00106	CbGpPWpGaD
Linezolid—MAOB—Metabolism—MTR—hematologic cancer	0.000107	0.00106	CbGpPWpGaD
Linezolid—Headache—Mitoxantrone—hematologic cancer	0.000107	0.000119	CcSEcCtD
Linezolid—Headache—Irinotecan—hematologic cancer	0.000107	0.000119	CcSEcCtD
Linezolid—Nausea—Ifosfamide—hematologic cancer	0.000107	0.000119	CcSEcCtD
Linezolid—Diarrhoea—Cisplatin—hematologic cancer	0.000106	0.000118	CcSEcCtD
Linezolid—Erythema multiforme—Epirubicin—hematologic cancer	0.000106	0.000118	CcSEcCtD
Linezolid—Vomiting—Gemcitabine—hematologic cancer	0.000106	0.000118	CcSEcCtD
Linezolid—Insomnia—Dexamethasone—hematologic cancer	0.000106	0.000118	CcSEcCtD
Linezolid—Insomnia—Betamethasone—hematologic cancer	0.000106	0.000118	CcSEcCtD
Linezolid—MAOB—Metabolism—ENO2—hematologic cancer	0.000105	0.00104	CbGpPWpGaD
Linezolid—Paraesthesia—Betamethasone—hematologic cancer	0.000105	0.000117	CcSEcCtD
Linezolid—Paraesthesia—Dexamethasone—hematologic cancer	0.000105	0.000117	CcSEcCtD
Linezolid—Rash—Gemcitabine—hematologic cancer	0.000105	0.000117	CcSEcCtD
Linezolid—Dermatitis—Gemcitabine—hematologic cancer	0.000105	0.000117	CcSEcCtD
Linezolid—Tinnitus—Epirubicin—hematologic cancer	0.000104	0.000117	CcSEcCtD
Linezolid—MAOA—Metabolism—FHL2—hematologic cancer	0.000104	0.00103	CbGpPWpGaD
Linezolid—Erythema—Methotrexate—hematologic cancer	0.000104	0.000116	CcSEcCtD
Linezolid—Haemoglobin—Doxorubicin—hematologic cancer	0.000104	0.000116	CcSEcCtD
Linezolid—Headache—Gemcitabine—hematologic cancer	0.000104	0.000116	CcSEcCtD
Linezolid—Nausea—Vincristine—hematologic cancer	0.000104	0.000116	CcSEcCtD
Linezolid—Haemorrhage—Doxorubicin—hematologic cancer	0.000104	0.000116	CcSEcCtD
Linezolid—Hypoaesthesia—Doxorubicin—hematologic cancer	0.000103	0.000115	CcSEcCtD
Linezolid—Pharyngitis—Doxorubicin—hematologic cancer	0.000103	0.000115	CcSEcCtD
Linezolid—Dyspepsia—Dexamethasone—hematologic cancer	0.000103	0.000115	CcSEcCtD
Linezolid—Dyspepsia—Betamethasone—hematologic cancer	0.000103	0.000115	CcSEcCtD
Linezolid—Urticaria—Triamcinolone—hematologic cancer	0.000102	0.000114	CcSEcCtD
Linezolid—MAOA—Metabolism—AGRN—hematologic cancer	0.000102	0.00101	CbGpPWpGaD
Linezolid—Dysgeusia—Methotrexate—hematologic cancer	0.000102	0.000114	CcSEcCtD
Linezolid—MAOB—Metabolism—GSTT1—hematologic cancer	0.000102	0.00101	CbGpPWpGaD
Linezolid—Asthenia—Etoposide—hematologic cancer	0.000102	0.000114	CcSEcCtD
Linezolid—Body temperature increased—Triamcinolone—hematologic cancer	0.000102	0.000114	CcSEcCtD
Linezolid—Anaphylactic shock—Prednisone—hematologic cancer	0.000102	0.000114	CcSEcCtD
Linezolid—Decreased appetite—Dexamethasone—hematologic cancer	0.000102	0.000113	CcSEcCtD
Linezolid—Decreased appetite—Betamethasone—hematologic cancer	0.000102	0.000113	CcSEcCtD
Linezolid—Nausea—Mitoxantrone—hematologic cancer	0.000101	0.000113	CcSEcCtD
Linezolid—Nausea—Irinotecan—hematologic cancer	0.000101	0.000113	CcSEcCtD
Linezolid—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000101	0.000113	CcSEcCtD
Linezolid—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000101	0.000113	CcSEcCtD
Linezolid—Fatigue—Betamethasone—hematologic cancer	0.000101	0.000112	CcSEcCtD
Linezolid—Fatigue—Dexamethasone—hematologic cancer	0.000101	0.000112	CcSEcCtD
Linezolid—Chills—Epirubicin—hematologic cancer	0.0001	0.000112	CcSEcCtD
Linezolid—Pruritus—Etoposide—hematologic cancer	0.0001	0.000112	CcSEcCtD
Linezolid—Pain—Betamethasone—hematologic cancer	9.99e-05	0.000111	CcSEcCtD
Linezolid—Pain—Dexamethasone—hematologic cancer	9.99e-05	0.000111	CcSEcCtD
Linezolid—MAOB—Metabolism—SDC1—hematologic cancer	9.96e-05	0.000986	CbGpPWpGaD
Linezolid—Skin disorder—Prednisone—hematologic cancer	9.88e-05	0.00011	CcSEcCtD
Linezolid—Nausea—Gemcitabine—hematologic cancer	9.87e-05	0.00011	CcSEcCtD
Linezolid—Vomiting—Cisplatin—hematologic cancer	9.85e-05	0.00011	CcSEcCtD
Linezolid—Hyperhidrosis—Prednisone—hematologic cancer	9.83e-05	0.00011	CcSEcCtD
Linezolid—Vision blurred—Methotrexate—hematologic cancer	9.82e-05	0.00011	CcSEcCtD
Linezolid—Erythema multiforme—Doxorubicin—hematologic cancer	9.8e-05	0.000109	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—TNF—hematologic cancer	9.8e-05	0.00097	CbGpPWpGaD
Linezolid—Rash—Cisplatin—hematologic cancer	9.77e-05	0.000109	CcSEcCtD
Linezolid—Dermatitis—Cisplatin—hematologic cancer	9.76e-05	0.000109	CcSEcCtD
Linezolid—Erythema—Epirubicin—hematologic cancer	9.75e-05	0.000109	CcSEcCtD
Linezolid—Diarrhoea—Etoposide—hematologic cancer	9.71e-05	0.000108	CcSEcCtD
Linezolid—Anorexia—Prednisone—hematologic cancer	9.7e-05	0.000108	CcSEcCtD
Linezolid—MAOA—Metabolism—HMMR—hematologic cancer	9.69e-05	0.00096	CbGpPWpGaD
Linezolid—MAOA—Metabolism—IDH2—hematologic cancer	9.69e-05	0.00096	CbGpPWpGaD
Linezolid—Tinnitus—Doxorubicin—hematologic cancer	9.66e-05	0.000108	CcSEcCtD
Linezolid—Anaemia—Methotrexate—hematologic cancer	9.63e-05	0.000107	CcSEcCtD
Linezolid—Flatulence—Epirubicin—hematologic cancer	9.61e-05	0.000107	CcSEcCtD
Linezolid—Gastrointestinal pain—Betamethasone—hematologic cancer	9.55e-05	0.000107	CcSEcCtD
Linezolid—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.55e-05	0.000107	CcSEcCtD
Linezolid—Dysgeusia—Epirubicin—hematologic cancer	9.55e-05	0.000107	CcSEcCtD
Linezolid—MAOA—Neuronal System—MDM2—hematologic cancer	9.45e-05	0.000937	CbGpPWpGaD
Linezolid—Dizziness—Etoposide—hematologic cancer	9.38e-05	0.000105	CcSEcCtD
Linezolid—Muscle spasms—Epirubicin—hematologic cancer	9.37e-05	0.000105	CcSEcCtD
Linezolid—Vertigo—Methotrexate—hematologic cancer	9.36e-05	0.000104	CcSEcCtD
Linezolid—Leukopenia—Methotrexate—hematologic cancer	9.32e-05	0.000104	CcSEcCtD
Linezolid—Chills—Doxorubicin—hematologic cancer	9.3e-05	0.000104	CcSEcCtD
Linezolid—Urticaria—Betamethasone—hematologic cancer	9.28e-05	0.000104	CcSEcCtD
Linezolid—Urticaria—Dexamethasone—hematologic cancer	9.28e-05	0.000104	CcSEcCtD
Linezolid—Dizziness—Prednisolone—hematologic cancer	9.26e-05	0.000103	CcSEcCtD
Linezolid—Asthenia—Triamcinolone—hematologic cancer	9.24e-05	0.000103	CcSEcCtD
Linezolid—Abdominal pain—Dexamethasone—hematologic cancer	9.23e-05	0.000103	CcSEcCtD
Linezolid—Body temperature increased—Betamethasone—hematologic cancer	9.23e-05	0.000103	CcSEcCtD
Linezolid—Abdominal pain—Betamethasone—hematologic cancer	9.23e-05	0.000103	CcSEcCtD
Linezolid—Body temperature increased—Dexamethasone—hematologic cancer	9.23e-05	0.000103	CcSEcCtD
Linezolid—Nausea—Cisplatin—hematologic cancer	9.2e-05	0.000103	CcSEcCtD
Linezolid—Insomnia—Prednisone—hematologic cancer	9.2e-05	0.000103	CcSEcCtD
Linezolid—Vision blurred—Epirubicin—hematologic cancer	9.19e-05	0.000103	CcSEcCtD
Linezolid—Paraesthesia—Prednisone—hematologic cancer	9.13e-05	0.000102	CcSEcCtD
Linezolid—MAOA—Metabolism—ARNTL—hematologic cancer	9.11e-05	0.000903	CbGpPWpGaD
Linezolid—Pruritus—Triamcinolone—hematologic cancer	9.11e-05	0.000102	CcSEcCtD
Linezolid—Cough—Methotrexate—hematologic cancer	9.09e-05	0.000101	CcSEcCtD
Linezolid—Convulsion—Methotrexate—hematologic cancer	9.02e-05	0.000101	CcSEcCtD
Linezolid—Vomiting—Etoposide—hematologic cancer	9.02e-05	0.000101	CcSEcCtD
Linezolid—Erythema—Doxorubicin—hematologic cancer	9.02e-05	0.000101	CcSEcCtD
Linezolid—Anaemia—Epirubicin—hematologic cancer	9.01e-05	0.000101	CcSEcCtD
Linezolid—Dyspepsia—Prednisone—hematologic cancer	8.95e-05	9.99e-05	CcSEcCtD
Linezolid—Rash—Etoposide—hematologic cancer	8.95e-05	9.99e-05	CcSEcCtD
Linezolid—Dermatitis—Etoposide—hematologic cancer	8.94e-05	9.98e-05	CcSEcCtD
Linezolid—Headache—Etoposide—hematologic cancer	8.89e-05	9.92e-05	CcSEcCtD
Linezolid—Flatulence—Doxorubicin—hematologic cancer	8.89e-05	9.92e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—CA9—hematologic cancer	8.87e-05	0.000878	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ACP5—hematologic cancer	8.87e-05	0.000878	CbGpPWpGaD
Linezolid—Decreased appetite—Prednisone—hematologic cancer	8.84e-05	9.87e-05	CcSEcCtD
Linezolid—Dysgeusia—Doxorubicin—hematologic cancer	8.83e-05	9.86e-05	CcSEcCtD
Linezolid—Rash—Prednisolone—hematologic cancer	8.83e-05	9.85e-05	CcSEcCtD
Linezolid—Dermatitis—Prednisolone—hematologic cancer	8.82e-05	9.84e-05	CcSEcCtD
Linezolid—Fatigue—Prednisone—hematologic cancer	8.77e-05	9.79e-05	CcSEcCtD
Linezolid—Headache—Prednisolone—hematologic cancer	8.77e-05	9.79e-05	CcSEcCtD
Linezolid—Vertigo—Epirubicin—hematologic cancer	8.76e-05	9.77e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—NCOR2—hematologic cancer	8.75e-05	0.000867	CbGpPWpGaD
Linezolid—Leukopenia—Epirubicin—hematologic cancer	8.73e-05	9.74e-05	CcSEcCtD
Linezolid—Constipation—Prednisone—hematologic cancer	8.7e-05	9.71e-05	CcSEcCtD
Linezolid—Muscle spasms—Doxorubicin—hematologic cancer	8.67e-05	9.68e-05	CcSEcCtD
Linezolid—Dizziness—Triamcinolone—hematologic cancer	8.51e-05	9.5e-05	CcSEcCtD
Linezolid—Cough—Epirubicin—hematologic cancer	8.51e-05	9.49e-05	CcSEcCtD
Linezolid—Anaphylactic shock—Methotrexate—hematologic cancer	8.5e-05	9.49e-05	CcSEcCtD
Linezolid—Vision blurred—Doxorubicin—hematologic cancer	8.5e-05	9.49e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—NQO1—hematologic cancer	8.46e-05	0.000839	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CD44—hematologic cancer	8.46e-05	0.000839	CbGpPWpGaD
Linezolid—Convulsion—Epirubicin—hematologic cancer	8.45e-05	9.42e-05	CcSEcCtD
Linezolid—Nausea—Etoposide—hematologic cancer	8.43e-05	9.41e-05	CcSEcCtD
Linezolid—Hypertension—Epirubicin—hematologic cancer	8.42e-05	9.39e-05	CcSEcCtD
Linezolid—Asthenia—Dexamethasone—hematologic cancer	8.38e-05	9.35e-05	CcSEcCtD
Linezolid—Asthenia—Betamethasone—hematologic cancer	8.38e-05	9.35e-05	CcSEcCtD
Linezolid—Anaemia—Doxorubicin—hematologic cancer	8.34e-05	9.3e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—IDH1—hematologic cancer	8.34e-05	0.000826	CbGpPWpGaD
Linezolid—Thrombocytopenia—Methotrexate—hematologic cancer	8.32e-05	9.29e-05	CcSEcCtD
Linezolid—Gastrointestinal pain—Prednisone—hematologic cancer	8.32e-05	9.28e-05	CcSEcCtD
Linezolid—Nausea—Prednisolone—hematologic cancer	8.31e-05	9.28e-05	CcSEcCtD
Linezolid—Pruritus—Dexamethasone—hematologic cancer	8.26e-05	9.22e-05	CcSEcCtD
Linezolid—Pruritus—Betamethasone—hematologic cancer	8.26e-05	9.22e-05	CcSEcCtD
Linezolid—Skin disorder—Methotrexate—hematologic cancer	8.26e-05	9.21e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—TXN—hematologic cancer	8.24e-05	0.000817	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ABCC3—hematologic cancer	8.24e-05	0.000817	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTO1—hematologic cancer	8.24e-05	0.000817	CbGpPWpGaD
Linezolid—Hyperhidrosis—Methotrexate—hematologic cancer	8.22e-05	9.17e-05	CcSEcCtD
Linezolid—Vomiting—Triamcinolone—hematologic cancer	8.18e-05	9.13e-05	CcSEcCtD
Linezolid—Rash—Triamcinolone—hematologic cancer	8.12e-05	9.06e-05	CcSEcCtD
Linezolid—Dry mouth—Epirubicin—hematologic cancer	8.12e-05	9.06e-05	CcSEcCtD
Linezolid—Dermatitis—Triamcinolone—hematologic cancer	8.11e-05	9.05e-05	CcSEcCtD
Linezolid—Vertigo—Doxorubicin—hematologic cancer	8.1e-05	9.04e-05	CcSEcCtD
Linezolid—Anorexia—Methotrexate—hematologic cancer	8.1e-05	9.04e-05	CcSEcCtD
Linezolid—Urticaria—Prednisone—hematologic cancer	8.08e-05	9.02e-05	CcSEcCtD
Linezolid—Leukopenia—Doxorubicin—hematologic cancer	8.07e-05	9.01e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—SPHK1—hematologic cancer	8.07e-05	0.000799	CbGpPWpGaD
Linezolid—Headache—Triamcinolone—hematologic cancer	8.06e-05	9e-05	CcSEcCtD
Linezolid—Abdominal pain—Prednisone—hematologic cancer	8.04e-05	8.97e-05	CcSEcCtD
Linezolid—Body temperature increased—Prednisone—hematologic cancer	8.04e-05	8.97e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—CYCS—hematologic cancer	8.01e-05	0.000794	CbGpPWpGaD
Linezolid—Diarrhoea—Betamethasone—hematologic cancer	7.99e-05	8.92e-05	CcSEcCtD
Linezolid—Diarrhoea—Dexamethasone—hematologic cancer	7.99e-05	8.92e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—HSP90AA1—hematologic cancer	7.96e-05	0.000788	CbGpPWpGaD
Linezolid—Anaphylactic shock—Epirubicin—hematologic cancer	7.96e-05	8.88e-05	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL6—hematologic cancer	7.91e-05	0.000783	CbGpPWpGaD
Linezolid—Cough—Doxorubicin—hematologic cancer	7.87e-05	8.78e-05	CcSEcCtD
Linezolid—Convulsion—Doxorubicin—hematologic cancer	7.81e-05	8.72e-05	CcSEcCtD
Linezolid—Thrombocytopenia—Epirubicin—hematologic cancer	7.79e-05	8.69e-05	CcSEcCtD
Linezolid—Hypertension—Doxorubicin—hematologic cancer	7.79e-05	8.69e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—UGT1A1—hematologic cancer	7.75e-05	0.000768	CbGpPWpGaD
Linezolid—Skin disorder—Epirubicin—hematologic cancer	7.73e-05	8.62e-05	CcSEcCtD
Linezolid—Dizziness—Dexamethasone—hematologic cancer	7.72e-05	8.62e-05	CcSEcCtD
Linezolid—Dizziness—Betamethasone—hematologic cancer	7.72e-05	8.62e-05	CcSEcCtD
Linezolid—Hyperhidrosis—Epirubicin—hematologic cancer	7.69e-05	8.58e-05	CcSEcCtD
Linezolid—Insomnia—Methotrexate—hematologic cancer	7.69e-05	8.58e-05	CcSEcCtD
Linezolid—Nausea—Triamcinolone—hematologic cancer	7.65e-05	8.53e-05	CcSEcCtD
Linezolid—Paraesthesia—Methotrexate—hematologic cancer	7.63e-05	8.52e-05	CcSEcCtD
Linezolid—Anorexia—Epirubicin—hematologic cancer	7.58e-05	8.46e-05	CcSEcCtD
Linezolid—Dyspnoea—Methotrexate—hematologic cancer	7.58e-05	8.46e-05	CcSEcCtD
Linezolid—Somnolence—Methotrexate—hematologic cancer	7.56e-05	8.43e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—SLC22A1—hematologic cancer	7.54e-05	0.000747	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CRABP1—hematologic cancer	7.54e-05	0.000747	CbGpPWpGaD
Linezolid—Dry mouth—Doxorubicin—hematologic cancer	7.51e-05	8.38e-05	CcSEcCtD
Linezolid—Dyspepsia—Methotrexate—hematologic cancer	7.48e-05	8.35e-05	CcSEcCtD
Linezolid—Vomiting—Dexamethasone—hematologic cancer	7.43e-05	8.29e-05	CcSEcCtD
Linezolid—Vomiting—Betamethasone—hematologic cancer	7.43e-05	8.29e-05	CcSEcCtD
Linezolid—Decreased appetite—Methotrexate—hematologic cancer	7.39e-05	8.25e-05	CcSEcCtD
Linezolid—Rash—Dexamethasone—hematologic cancer	7.36e-05	8.22e-05	CcSEcCtD
Linezolid—Rash—Betamethasone—hematologic cancer	7.36e-05	8.22e-05	CcSEcCtD
Linezolid—Anaphylactic shock—Doxorubicin—hematologic cancer	7.36e-05	8.21e-05	CcSEcCtD
Linezolid—Dermatitis—Betamethasone—hematologic cancer	7.36e-05	8.21e-05	CcSEcCtD
Linezolid—Dermatitis—Dexamethasone—hematologic cancer	7.36e-05	8.21e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—ALOX5—hematologic cancer	7.35e-05	0.000728	CbGpPWpGaD
Linezolid—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.34e-05	8.19e-05	CcSEcCtD
Linezolid—Fatigue—Methotrexate—hematologic cancer	7.33e-05	8.18e-05	CcSEcCtD
Linezolid—Headache—Betamethasone—hematologic cancer	7.32e-05	8.17e-05	CcSEcCtD
Linezolid—Headache—Dexamethasone—hematologic cancer	7.32e-05	8.17e-05	CcSEcCtD
Linezolid—Asthenia—Prednisone—hematologic cancer	7.3e-05	8.14e-05	CcSEcCtD
Linezolid—Pain—Methotrexate—hematologic cancer	7.27e-05	8.11e-05	CcSEcCtD
Linezolid—Thrombocytopenia—Doxorubicin—hematologic cancer	7.21e-05	8.04e-05	CcSEcCtD
Linezolid—Pruritus—Prednisone—hematologic cancer	7.2e-05	8.03e-05	CcSEcCtD
Linezolid—Insomnia—Epirubicin—hematologic cancer	7.2e-05	8.03e-05	CcSEcCtD
Linezolid—Skin disorder—Doxorubicin—hematologic cancer	7.15e-05	7.98e-05	CcSEcCtD
Linezolid—Paraesthesia—Epirubicin—hematologic cancer	7.14e-05	7.97e-05	CcSEcCtD
Linezolid—Hyperhidrosis—Doxorubicin—hematologic cancer	7.12e-05	7.94e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—NUP98—hematologic cancer	7.12e-05	0.000705	CbGpPWpGaD
Linezolid—Dyspnoea—Epirubicin—hematologic cancer	7.09e-05	7.91e-05	CcSEcCtD
Linezolid—Somnolence—Epirubicin—hematologic cancer	7.07e-05	7.89e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—GSTP1—hematologic cancer	7.06e-05	0.000699	CbGpPWpGaD
Linezolid—Anorexia—Doxorubicin—hematologic cancer	7.02e-05	7.83e-05	CcSEcCtD
Linezolid—Dyspepsia—Epirubicin—hematologic cancer	7e-05	7.81e-05	CcSEcCtD
Linezolid—Diarrhoea—Prednisone—hematologic cancer	6.96e-05	7.77e-05	CcSEcCtD
Linezolid—Gastrointestinal pain—Methotrexate—hematologic cancer	6.95e-05	7.76e-05	CcSEcCtD
Linezolid—Nausea—Betamethasone—hematologic cancer	6.94e-05	7.74e-05	CcSEcCtD
Linezolid—Nausea—Dexamethasone—hematologic cancer	6.94e-05	7.74e-05	CcSEcCtD
Linezolid—Decreased appetite—Epirubicin—hematologic cancer	6.92e-05	7.72e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—ADCY7—hematologic cancer	6.91e-05	0.000684	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NCOA3—hematologic cancer	6.91e-05	0.000684	CbGpPWpGaD
Linezolid—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.87e-05	7.66e-05	CcSEcCtD
Linezolid—Fatigue—Epirubicin—hematologic cancer	6.86e-05	7.65e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—NUP214—hematologic cancer	6.86e-05	0.000679	CbGpPWpGaD
Linezolid—Pain—Epirubicin—hematologic cancer	6.8e-05	7.59e-05	CcSEcCtD
Linezolid—Constipation—Epirubicin—hematologic cancer	6.8e-05	7.59e-05	CcSEcCtD
Linezolid—MAOA—Transmission across Chemical Synapses—HRAS—hematologic cancer	6.77e-05	0.000671	CbGpPWpGaD
Linezolid—Urticaria—Methotrexate—hematologic cancer	6.75e-05	7.54e-05	CcSEcCtD
Linezolid—Dizziness—Prednisone—hematologic cancer	6.73e-05	7.51e-05	CcSEcCtD
Linezolid—Body temperature increased—Methotrexate—hematologic cancer	6.72e-05	7.5e-05	CcSEcCtD
Linezolid—Abdominal pain—Methotrexate—hematologic cancer	6.72e-05	7.5e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—ABCG2—hematologic cancer	6.72e-05	0.000666	CbGpPWpGaD
Linezolid—MAOA—Metabolism—MTR—hematologic cancer	6.72e-05	0.000666	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ABCB1—hematologic cancer	6.68e-05	0.000662	CbGpPWpGaD
Linezolid—Insomnia—Doxorubicin—hematologic cancer	6.66e-05	7.43e-05	CcSEcCtD
Linezolid—Paraesthesia—Doxorubicin—hematologic cancer	6.61e-05	7.38e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—ENO2—hematologic cancer	6.59e-05	0.000653	CbGpPWpGaD
Linezolid—Dyspnoea—Doxorubicin—hematologic cancer	6.56e-05	7.32e-05	CcSEcCtD
Linezolid—Somnolence—Doxorubicin—hematologic cancer	6.54e-05	7.3e-05	CcSEcCtD
Linezolid—Gastrointestinal pain—Epirubicin—hematologic cancer	6.51e-05	7.26e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—GSTM1—hematologic cancer	6.49e-05	0.000643	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NCOR1—hematologic cancer	6.49e-05	0.000643	CbGpPWpGaD
Linezolid—Dyspepsia—Doxorubicin—hematologic cancer	6.48e-05	7.23e-05	CcSEcCtD
Linezolid—Vomiting—Prednisone—hematologic cancer	6.47e-05	7.22e-05	CcSEcCtD
Linezolid—Rash—Prednisone—hematologic cancer	6.41e-05	7.16e-05	CcSEcCtD
Linezolid—Dermatitis—Prednisone—hematologic cancer	6.41e-05	7.15e-05	CcSEcCtD
Linezolid—Decreased appetite—Doxorubicin—hematologic cancer	6.4e-05	7.14e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—GSTT1—hematologic cancer	6.39e-05	0.000633	CbGpPWpGaD
Linezolid—Headache—Prednisone—hematologic cancer	6.37e-05	7.11e-05	CcSEcCtD
Linezolid—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.35e-05	7.09e-05	CcSEcCtD
Linezolid—Fatigue—Doxorubicin—hematologic cancer	6.35e-05	7.08e-05	CcSEcCtD
Linezolid—Urticaria—Epirubicin—hematologic cancer	6.32e-05	7.05e-05	CcSEcCtD
Linezolid—Pain—Doxorubicin—hematologic cancer	6.29e-05	7.02e-05	CcSEcCtD
Linezolid—Constipation—Doxorubicin—hematologic cancer	6.29e-05	7.02e-05	CcSEcCtD
Linezolid—Body temperature increased—Epirubicin—hematologic cancer	6.29e-05	7.02e-05	CcSEcCtD
Linezolid—Abdominal pain—Epirubicin—hematologic cancer	6.29e-05	7.02e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—SDC1—hematologic cancer	6.25e-05	0.000619	CbGpPWpGaD
Linezolid—Asthenia—Methotrexate—hematologic cancer	6.1e-05	6.81e-05	CcSEcCtD
Linezolid—Nausea—Prednisone—hematologic cancer	6.04e-05	6.74e-05	CcSEcCtD
Linezolid—Gastrointestinal pain—Doxorubicin—hematologic cancer	6.02e-05	6.72e-05	CcSEcCtD
Linezolid—Pruritus—Methotrexate—hematologic cancer	6.01e-05	6.71e-05	CcSEcCtD
Linezolid—Urticaria—Doxorubicin—hematologic cancer	5.85e-05	6.53e-05	CcSEcCtD
Linezolid—Abdominal pain—Doxorubicin—hematologic cancer	5.82e-05	6.49e-05	CcSEcCtD
Linezolid—Body temperature increased—Doxorubicin—hematologic cancer	5.82e-05	6.49e-05	CcSEcCtD
Linezolid—Diarrhoea—Methotrexate—hematologic cancer	5.82e-05	6.49e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—MTHFR—hematologic cancer	5.73e-05	0.000568	CbGpPWpGaD
Linezolid—Asthenia—Epirubicin—hematologic cancer	5.71e-05	6.37e-05	CcSEcCtD
Linezolid—Pruritus—Epirubicin—hematologic cancer	5.63e-05	6.28e-05	CcSEcCtD
Linezolid—Dizziness—Methotrexate—hematologic cancer	5.62e-05	6.27e-05	CcSEcCtD
Linezolid—Diarrhoea—Epirubicin—hematologic cancer	5.44e-05	6.07e-05	CcSEcCtD
Linezolid—Vomiting—Methotrexate—hematologic cancer	5.4e-05	6.03e-05	CcSEcCtD
Linezolid—Rash—Methotrexate—hematologic cancer	5.36e-05	5.98e-05	CcSEcCtD
Linezolid—Dermatitis—Methotrexate—hematologic cancer	5.35e-05	5.98e-05	CcSEcCtD
Linezolid—Headache—Methotrexate—hematologic cancer	5.33e-05	5.94e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—CD44—hematologic cancer	5.31e-05	0.000526	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NQO1—hematologic cancer	5.31e-05	0.000526	CbGpPWpGaD
Linezolid—Asthenia—Doxorubicin—hematologic cancer	5.28e-05	5.89e-05	CcSEcCtD
Linezolid—Dizziness—Epirubicin—hematologic cancer	5.26e-05	5.87e-05	CcSEcCtD
Linezolid—Pruritus—Doxorubicin—hematologic cancer	5.21e-05	5.81e-05	CcSEcCtD
Linezolid—MAOA—Neuronal System—HRAS—hematologic cancer	5.19e-05	0.000514	CbGpPWpGaD
Linezolid—Vomiting—Epirubicin—hematologic cancer	5.06e-05	5.64e-05	CcSEcCtD
Linezolid—Nausea—Methotrexate—hematologic cancer	5.05e-05	5.63e-05	CcSEcCtD
Linezolid—Diarrhoea—Doxorubicin—hematologic cancer	5.04e-05	5.62e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—CYCS—hematologic cancer	5.03e-05	0.000498	CbGpPWpGaD
Linezolid—Rash—Epirubicin—hematologic cancer	5.02e-05	5.6e-05	CcSEcCtD
Linezolid—Dermatitis—Epirubicin—hematologic cancer	5.01e-05	5.59e-05	CcSEcCtD
Linezolid—MAOA—Metabolism—HSP90AA1—hematologic cancer	4.99e-05	0.000495	CbGpPWpGaD
Linezolid—Headache—Epirubicin—hematologic cancer	4.98e-05	5.56e-05	CcSEcCtD
Linezolid—Dizziness—Doxorubicin—hematologic cancer	4.87e-05	5.43e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—PIK3CG—hematologic cancer	4.82e-05	0.000477	CbGpPWpGaD
Linezolid—Nausea—Epirubicin—hematologic cancer	4.73e-05	5.27e-05	CcSEcCtD
Linezolid—Vomiting—Doxorubicin—hematologic cancer	4.68e-05	5.22e-05	CcSEcCtD
Linezolid—Rash—Doxorubicin—hematologic cancer	4.64e-05	5.18e-05	CcSEcCtD
Linezolid—Dermatitis—Doxorubicin—hematologic cancer	4.64e-05	5.17e-05	CcSEcCtD
Linezolid—Headache—Doxorubicin—hematologic cancer	4.61e-05	5.15e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—CREBBP—hematologic cancer	4.47e-05	0.000442	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTP1—hematologic cancer	4.43e-05	0.000439	CbGpPWpGaD
Linezolid—Nausea—Doxorubicin—hematologic cancer	4.37e-05	4.88e-05	CcSEcCtD
Linezolid—MAOB—Metabolism—PIK3CD—hematologic cancer	4.23e-05	0.00042	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ABCB1—hematologic cancer	4.19e-05	0.000415	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALB—hematologic cancer	4.18e-05	0.000414	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTM1—hematologic cancer	4.07e-05	0.000403	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NCOR1—hematologic cancer	4.07e-05	0.000403	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3R1—hematologic cancer	4e-05	0.000396	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CB—hematologic cancer	3.69e-05	0.000366	CbGpPWpGaD
Linezolid—MAOA—Metabolism—MTHFR—hematologic cancer	3.6e-05	0.000356	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTEN—hematologic cancer	3.19e-05	0.000316	CbGpPWpGaD
Linezolid—MAOB—Metabolism—EP300—hematologic cancer	3.04e-05	0.000301	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CG—hematologic cancer	3.02e-05	0.000299	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CREBBP—hematologic cancer	2.8e-05	0.000278	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CD—hematologic cancer	2.66e-05	0.000263	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ALB—hematologic cancer	2.62e-05	0.00026	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3R1—hematologic cancer	2.51e-05	0.000249	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CB—hematologic cancer	2.32e-05	0.000229	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CA—hematologic cancer	2.25e-05	0.000223	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTEN—hematologic cancer	2e-05	0.000198	CbGpPWpGaD
Linezolid—MAOA—Metabolism—EP300—hematologic cancer	1.91e-05	0.000189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AKT1—hematologic cancer	1.84e-05	0.000182	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CA—hematologic cancer	1.41e-05	0.00014	CbGpPWpGaD
Linezolid—MAOA—Metabolism—AKT1—hematologic cancer	1.15e-05	0.000114	CbGpPWpGaD
